IN8BIO INC. - COMMON STOCK

IN8bio Reports First Quarter 2024 Financial Results and Recent Corporate Highlights

09 May 2024 16:00:00 By Nasdaq GlobeNewswire

IN8bio Doses First Patient in Phase 2 Clinical Trial of INB-400 in Newly Diagnosed Glioblastoma

30 Apr 2024 06:05:00 By Nasdaq GlobeNewswire

IN8bio Announces Oral Presentation at the Upcoming American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting

24 Apr 2024 08:00:00 By Nasdaq GlobeNewswire

IN8bio to Present at Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference

16 Apr 2024 16:05:00 By Nasdaq GlobeNewswire

IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024

09 Apr 2024 16:30:00 By Nasdaq GlobeNewswire

IN8bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights

14 Mar 2024 16:00:00 By Nasdaq GlobeNewswire

IN8bio to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR Annual Meeting 2024

05 Mar 2024 16:30:00 By Nasdaq GlobeNewswire

IN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in Immunology

14 Feb 2024 08:00:00 By Nasdaq GlobeNewswire

IN8bio Highlights Recent Company Accomplishments and Outlines 2024 Pipeline Goals

04 Jan 2024 08:00:00 By Nasdaq GlobeNewswire

IN8bio Announces Positive Clinical Update Demonstrating Continued Durable Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100 in Leukemia

11 Dec 2023 16:05:00 By Nasdaq GlobeNewswire

IN8bio Announces Pricing of Financing Totaling up to $46.9 Million in Private Placement

11 Dec 2023 09:00:47 By Nasdaq GlobeNewswire

IN8bio Appoints Dr. Corinne Epperly to Board of Directors

07 Dec 2023 08:00:00 By Nasdaq GlobeNewswire

IN8bio to Host Investor Call at 8:30 AM ET on Tuesday, December 12 to Discuss Updated Clinical Data from Phase 1 Trial of INB-100 in Patients with Leukemia

05 Dec 2023 08:00:00 By Nasdaq GlobeNewswire

IN8bio’s INB-200 Demonstrates Extended Progression-Free Survival in Patients with Newly Diagnosed Glioblastoma

20 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

IN8bio to Present Data Highlighting Potential of INB-200 and INB-400 to Treat Patients with Newly Diagnosed Glioblastoma Multiforme at Society for Neuro-Oncology 28th Annual Meeting

10 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

IN8bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update

09 Nov 2023 16:00:00 By Nasdaq GlobeNewswire

IN8bio Presents Biologic Correlative Data from the INB-200 Phase 1 Trial in Newly Diagnosed Glioblastoma at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

06 Nov 2023 08:00:00 By Nasdaq GlobeNewswire

IN8bio Presents Positive Data Update from Induced Pluripotent Stem Cell (iPSC) Platform at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

03 Nov 2023 12:00:00 By Nasdaq GlobeNewswire

IN8bio to Present New Positive Data from Phase 1 Trial of INB-100 at 2023 American Society of Hematology (ASH) Annual Meeting

02 Nov 2023 09:17:21 By Nasdaq GlobeNewswire

IN8bio to Participate at the 2023 Truist Securities BioPharma Symposium

01 Nov 2023 08:00:01 By Nasdaq GlobeNewswire